Drug intelligence / Profile preview

CDX-6114

Development stage: Phase 1
Lead developer: Nestlé Health Science
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Oral

Overview

CDX-6114 is an orally administered, gastrointestinal-stable, modified phenylalanine ammonia lyase (PAL) enzyme developed for the treatment of phenylketonuria (PKU). It acts by converting dietary phenylalanine (Phe) in the gastrointestinal tract into cinnamic acid and ammonia before systemic absorption, thereby reducing blood Phe levels. This mechanism compensates for the missing or deficient natural enzyme in PKU patients. The drug is designed to be stable in the GI tract and offers a potential oral alternative to restrictive diets currently used for PKU management. Clinical trials have shown that single doses are safe and well tolerated[1][6][5].

Brand names: PhenFlo
Other names: Phenylketonuria therapeutic enzymePAL-like enzyme

Beyond the preview

Go deeper on CDX-6114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDX-6114.

Explore the full profile